Value of Extracellular High Mobility Group Box 1 (HMGB1) in the Clinical Context of Immune Thrombocytopenia

J Clin Exp Invest 2019;10(2):em00724.

https://doi.org/10.5799/jcei/5833

OPEN ACCESS

Download Full Text (PDF)

Abstract

Introduction: High mobility group box 1 protein (HMGB1) is a non-histone chromosomal protein with dual activity. First within the nucleus, binds to DNA and acts as a regulator and second, outside the cell, interacts with receptors for inflammation as a signal molecule. We aimed to investigate and contribute to the value of extracellular HMGB1 in clinical context of ITP and to flourish future clinical directions to this biomarker.
Methods: 50 newly diagnosed and treatment naive patients with ITP and 30 healthy controls were enrolled in our study.
Results: Age or gender were not related with HMGB1 levels in patients and controls. Platelet levels were significantly related with HMGB1. Especially in patients with platelet counts below 30.000/mm3 highest levels of HMGB1 were observed. Regarding clinical presentation, bleeding was related with low platelet counts and high HMGB1 levels. Response to corticosteroids was observed to be better in patients with high HMGB1 levels.
Conclusion: As a sample of autoinflammatory disorders, we observed a relation with extracellular HMGB1 levels and platelet levels in ITP patients. Corticosteroid response and HMGB1 relation supports the assumption of the value of HMGB1 as a potential surrogate of inflammation. This view should be evaluated with larger scale studies.

Keywords

immune thrombocytopenia, inflammation, cytokine

References

  • Ugrinova I, Pasheva E. HMGB1 Protein: A Therapeutic Target Inside and Outside the Cell. Adv Protein Chem Struct Biol. 2017;107:37-76. doi: 10.1016/bs.apcsb.2016.10.00 Epub 2016 Dec 2.
  • Kang R, Chen R, Zhang Q, Hou W, Wu S, Cao L, Huang J, Yu Y, Fan XG, Yan Z, Sun X, Wang H, Wang Q, Tsung A, Billiar TR, Zeh HJ 3rd, Lotze MT, Tang D. HMGB1 in health and disease. Mol Aspects Med. 2014 Dec;40:1-116. doi: 10.1016/j.mam.2014.05.001. Epub 2014 Jul 8.
  • Yanai H, Ban T, Wang Z, Choi MK, Kawamura T, Negishi H, Nakasato M, Lu Y,Hangai S, Koshiba R, Savitsky D, Ronfani L, Akira S, Bianchi ME, Honda K, Tamura T, Kodama T, Taniguchi T. HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses. Nature. 2009 Nov 5;462(7269):99-10 doi: 10.1038/nature08512.
  • Qiu Y, Yang J, Wang W, Zhao W, Peng F, Xiang Y, Chen G, Chen T, Chai C, Zheng S, Watkins DJ, Feng J. HMGB1-promoted and TLR2/4-dependent NK cell maturation and activation take part in rotavirus-induced murine biliary atresia. PLoS Pathog.2014 Mar 20;10(3):e1004011. doi: 10.1371/journal.ppat.1004011.
  • Bauer EM, Shapiro R, Billiar TR, Bauer PM. High mobility group Box 1 inhibits human pulmonary artery endothelial cell migration via a Toll-like receptor 4- and interferon response factor 3-dependent mechanism(s). J Biol Chem. 2013 Jan 11;288(2):1365-73. doi: 10.1074/jbc.M112.434142.
  • Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 2002 Jul 11;418(6894):191-5. doi: 10.1038/nature00858
  • Yang H, Hreggvidsdottir HS, Palmblad K, Wang H, Ochani M, Li J, Lu B, Chavan S, Rosas-Ballina M, Al-Abed Y, Akira S, Bierhaus A, Erlandsson-Harris H, Andersson U, Tracey KJ. A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci U S A. 2010 Jun 29;107(26):11942- doi: 10.1073/pnas.1003893107.
  • Kang R, Zhang Q, Zeh HJ 3rd, Lotze MT, Tang D. HMGB1 in cancer: good, bad, or both? Clin Cancer Res. 2013 Aug 1;19(15):4046-57. doi: 10.1158/1078-0432.CCR-13-0495. Epub 2013 May 30.
  • Yang PF, Zhang GY, Liu HY, Xie SF, Wang XJ, Liu XY, Wang J, Chen XY, Yang S,Ma LP. [Expression of HMGB1 in Spleen of Adult Patients with Chronic and Refractory Immune Thrombocytopenia and Its Significance]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2018 Apr;26(2):516-521. doi: 10.7534/j.issn.1009-2137.2018.02.035.
  • Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N, Godeau B, Lechner K, Mazzucconi MG, McMillan R,Sanz MA, Imbach P, Blanchette V, Kühne T, Ruggeri M, George JN. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009 Mar 12;113(11):2386-93. doi: 1182/blood-2008-07-162503.
  • Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA; American Society of Hematology. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011 Apr 21;117(16):4190-207. doi: 10.1182/blood-2010-08-302984.
  • Toltl LJ, Arnold DM. Pathophysiology and management of chronic immune thrombocytopenia: focusing on what matters. Br J Haematol. 2011 Jan;152(1):52-60. doi: 10.1111/j.1365-2141.2010.084x. Epub 2010 Nov 18.
  • Venereau E, Schiraldi M, Uguccioni M, Bianchi ME. HMGB1 and leukocyte migration during trauma and sterile inflammation. Mol Immunol. 2013 Aug;55(1):76-82. doi: 10.1016/j.molimm.2012.10.037.
  • Kim SY, Son M, Lee SE, Park IH, Kwak MS, Han M, Lee HS, Kim ES, Kim JY, Lee JE, Choi JE, Diamond B, Shin JS. High-Mobility Group Box 1-Induced Complement Activation Causes Sterile Inflammation. Front Immunol. 2018 Apr 11;9:705. doi: 10.3389/fimmu.2018.00705.
  • Yang X, Wang H, Zhang M, Liu J, Lv B, Chen F. HMGB1: a novel protein that induced platelets active and aggregation via Toll-like receptor-4, NF-κB and cGMP dependent mechanisms. Diagn Pathol. 2015 Aug 6;10:134. doi: 10.1186/s13000-015-0348-3.
  • Wu H, Li R, Pei LG, Wei ZH, Kang LN, Wang L, Xie J, Xu B. Emerging Role of High Mobility Group Box-1 in Thrombosis-Related Diseases. Cell Physiol Biochem. 2018;47(4):1319-1337. doi: 10.1159/000490818.
  • Ito T, Kawahara K, Nakamura T, Yamada S, Nakamura T, Abeyama K, Hashiguchi T, Maruyama I. High-mobility group box 1 protein promotes development of microvascular thrombosis in rats. J Thromb Haemost. 2007 Jan;5(1):109-16.
  • Takahashi T, Shishido T, Kinoshita D, Watanabe K, Toshima T, Sugai T, Narumi T, Otaki Y, Tamura H, Nishiyama S, Arimoto T, Takahashi H, Miyamoto T, Watanabe T, Woo CH, Abe JI, Takeishi Y, Kubota I, Watanabe M. Cardiac Nuclear High-Mobility Group Box 1 Ameliorates Pathological Cardiac Hypertrophy by Inhibiting DNA Damage Response. JACC Basic Transl Sci. 2019 Apr 29;4(2):234-247.
  • Ye Y, Zeng Z, Jin T, Zhang H, Xiong X, Gu L. The Role of High Mobility Group Box 1 in Ischemic Stroke. Front Cell Neurosci. 2019 Apr 2;13:127
  • Yu S, Zhang H, Hei Y, Yi X, Baskys A, Liu W, Long Q. High mobility group box-1 (HMGB1) antagonist BoxA suppresses status epilepticus-induced neuroinflammatory responses associated with Toll-like receptor 2/4 down-regulation in rats. Brain Res. 2019 Apr 12. pii: S0006-8993(19)30200-8.
  • Frank MG, Annis JL, Watkins LR, Maier SF. Glucocorticoids mediate stress induction of the alarmin HMGB1 and reduction of the microglia checkpoint receptorCD200R1 in limbic brain structures. Brain Behav Immun. 2019 May 9. pii:S0889-1591(19)30279.
  • Meng R, Gu L, Lu Y, Zhao K, Wu J, Wang H, Han J, Tang Y, Lu B. High mobility group box 1 enables bacterial lipids to trigger receptor-interacting protein kinase 3 (RIPK3)-mediated necroptosis and apoptosis in mice. J Biol Chem. 2019 Apr 18. pii: jbc.RA118.007040.
  • Nakamura T, Kashima K, Takahashi N, Yamada S. Serum high mobility group box-1 and cytokine profiles in a leukemoid reaction. Pediatr Int. 2019 Apr;61(4):427-429
  • Chen C, Wang S, Chen J, Liu X, Zhang M, Wang X, Xu W, Zhang Y, Li H, Pan X,Si M. Escin suppresses HMGB1-induced overexpression of aquaporin-1 and increased permeability in endothelial cells. FEBS Open Bio. 2019 May;9(5):891-900.
  • Lin HJ, Hsu FY, Chen WW, Lee CH, Lin YJ, Chen YY, Chen CJ, Huang MZ, Kao MC, Chen YA, Lai HC, Lai CH. Helicobacter pylori Activates HMGB1 Expression and Recruits RAGE into Lipid Rafts to Promote Inflammation in Gastric Epithelial Cells. Front Immunol. 2016 Sep 9;7:341. doi: 10.3389/fimmu.2016.00341.

Citation

Umit EG, Baysal M, Bas V, Goze H, Asoglu V, Kirkizlar O, et al. Value of Extracellular High Mobility Group Box 1 (HMGB1) in the Clinical Context of Immune Thrombocytopenia. J Clin Exp Invest. 2019;10(2):em00724. https://doi.org/10.5799/jcei/5833